Merus N.V.. (2/27/17). "Press Release: Merus to Present at the Cowen & Co. 37th Annual Health Care Conference". Utrecht.

	Region	Boston, MA
	Country	United States (USA)
	Organisation	Merus N.V. (Nasdaq: MRUS)
	Group	Merus (Group)
	Organisation 2	Cowen & Company LLC
	Group	Cowen (Group)
	Product	Cowen & Co. Annual Health Care Conference 2017 Boston
	Product 2	Biclonics® antibody
	Index term	Merus–Cowen: investor conference, 201703 supply service Merus presents at Cowen & Co Annual Health Care Conference 2017
	Person	Logtenberg, Ton (Forbion 202203– Venture Partner formerly Merus Founder + CEO + U-BiSys Founder + CEO)
	Person 2	Schleifstein, Eliza (Argot Partners 201605)

Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen & Co. 37th Annual Health Care Conference on Monday, March 6, 2017 at 4:00 p.m. ET at the Boston Marriott Copley Place.

A live webcast of the presentation will be available on the Investors page of the Company's website,
http://www.merus.nl

An archived presentation will be available for 90 days.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Contacts:

Media:
Eliza Schleifstein
+1 973 361 1546
eliza@argotpartners.com

Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly@argotpartners.com

Merus N.V.

Record changed: 2023-06-05